Effect of Vocal Fold Injection of Cidofovir and Bevacizumab in a Porcine Model | Dermatology | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.212.130. Please contact the publisher to request reinstatement.
1.
Armstrong  LR, Derkay  CS, Reeves  WC; RRP Task Force.  Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis.  Arch Otolaryngol Head Neck Surg. 1999;125(7):743-748.PubMedGoogle ScholarCrossref
2.
Derkay  CS.  Task force on recurrent respiratory papillomas: a preliminary report.  Arch Otolaryngol Head Neck Surg. 1995;121(12):1386-1391.PubMedGoogle ScholarCrossref
3.
Derkay  CS, Wiatrak  B.  Recurrent respiratory papillomatosis: a review.  Laryngoscope. 2008;118(7):1236-1247.PubMedGoogle ScholarCrossref
4.
Reeves  WC, Ruparelia  SS, Swanson  KI, Derkay  CS, Marcus  A, Unger  ER.  National registry for juvenile-onset recurrent respiratory papillomatosis.  Arch Otolaryngol Head Neck Surg. 2003;129(9):976-982.PubMedGoogle ScholarCrossref
5.
Campisi  P, Hawkes  M, Simpson  K; Canadian Juvenile Onset Recurrent Respiratory Papillomatosis Working Group.  The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database.  Laryngoscope. 2010;120(6):1233-1245.PubMedGoogle Scholar
6.
Maturo  S, Hartnick  CJ.  Use of 532-nm pulsed potassium titanyl phosphate laser and adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children: initial experience.  Arch Otolaryngol Head Neck Surg. 2010;136(6):561-565.PubMedGoogle ScholarCrossref
7.
Lott  DG, Krakovitz  PR.  Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis.  Laryngoscope. 2009;119(3):567-570.PubMedGoogle ScholarCrossref
8.
Wemer  RD, Lee  JH, Hoffman  HT, Robinson  RA, Smith  RJ.  Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis.  Ann Otol Rhinol Laryngol. 2005;114(11):836-839.PubMedGoogle Scholar
9.
Chhetri  DK, Jahan-Parwar  B, Hart  SD, Bhuta  SM, Berke  GS, Shapiro  NL.  Local and systemic effects of intralaryngeal injection of cidofovir in a canine model.  Laryngoscope. 2003;113(11):1922-1926.PubMedGoogle ScholarCrossref
10.
Derkay  C; Multi-Disciplinary Task Force on Recurrent Respiratory Papillomas.  Cidofovir for recurrent respiratory papillomatosis: a re-assessment of risks.  Int J Pediatr Otorhinolaryngol. 2005;69(11):1465-1467.PubMedGoogle ScholarCrossref
11.
Rahbar  R, Vargas  SO, Folkman  J,  et al.  Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis.  Ann Otol Rhinol Laryngol. 2005;114(4):289-295.PubMedGoogle Scholar
12.
Zeitels  SM, Lopez-Guerra  G, Burns  JA, Lutch  M, Friedman  AM, Hillman  RE.  Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis.  Ann Otol Rhinol Laryngol Suppl. 2009;201:1-13.PubMedGoogle Scholar
13.
Zeitels  SM, Barbu  AM, Landau-Zemer  T,  et al.  Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study.  Ann Otol Rhinol Laryngol. 2011;120(10):627-634.PubMedGoogle Scholar
14.
Jiang  JJ, Raviv  JR, Hanson  DG.  Comparison of the phonation-related structures among pig, dog, white-tailed deer, and human larynges.  Ann Otol Rhinol Laryngol. 2001;110(12):1120-1125.PubMedGoogle Scholar
15.
Karita  S, Jagata  K, Hirano  M. A comparative study of the vocal folds. In: Bless  DM, Abbs  JH, eds.  Vocal Fold Physiology. San Diego, CA: College Hill Press; 1981:3-21.
16.
Naiman  AN, Ceruse  P, Coulombeau  B, Froehlich  P.  Intralesional cidofovir and surgical excision for laryngeal papillomatosis.  Laryngoscope. 2003;113(12):2174-2181.PubMedGoogle ScholarCrossref
17.
Derkay  CS, Volsky  PG, Rosen  CA,  et al.  Current use of intralesional cidofovir for recurrent respiratory papillomatosis.  Laryngoscope. 2013;123(3):705-712.PubMedGoogle ScholarCrossref
18.
Best  SR, Friedman  AD, Landau-Zemer  T,  et al.  Safety and dosing of bevacizumab (Avastin) for the treatment of recurrent respiratory papillomatosis.  Ann Otol Rhinol Laryngol. 2012;121(9):587-593.PubMedGoogle Scholar
19.
Alipour  F, Jaiswal  S.  Glottal airflow resistance in excised pig, sheep, and cow larynges.  J Voice. 2009;23(1):40-50.PubMedGoogle ScholarCrossref
Original Investigation
February 2014

Effect of Vocal Fold Injection of Cidofovir and Bevacizumab in a Porcine Model

Author Affiliations
  • 1Department of Otolaryngology, San Antonio Military Medical Center, Ft Sam Houston, Texas
  • 2Department of Pathobiology, 59th Clinical Research Division, Lackland Air Force Base, Texas
  • 3Department of Pathology, San Antonio Military Medical Center, Ft Sam Houston, Texas
  • 4Department of Otolaryngology, Lakenheath Air Force Base, England
  • 5Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • 6Uniformed Services University of the Health Sciences, Bethesda, Maryland
JAMA Otolaryngol Head Neck Surg. 2014;140(2):155-159. doi:10.1001/jamaoto.2013.5853
Abstract

Importance  Recurrent respiratory papillomatosis (RRP) is a common and often chronic disorder. Intralaryngeal bevacizumab has gained recent interest as an adjuvant therapy for RRP. However, no histologic model has been published describing the effects of bevacizumab on the vocal fold.

Objective  To investigate the histologic effects of bevacizumab injections into the vocal fold and compare these findings with those for cidofovir and saline control injections.

Design and Setting  In vivo animal study involving eighteen 1-year-old Yorkshire crossbreed pigs, with a blinded review of pathologic findings conducted in a veterinary research laboratory.

Interventions  The pigs were randomly divided into six study groups receiving 2.5 or 5.0 mg of cidofovir or bevacizumab alone or in combination. Each pig received an injection of 0.5 mL of the test drug in the right vocal fold and 0.5 mL of saline in the left vocal fold. These injections were performed 4 times during the course of 8 weeks. One pig from each group was killed humanely and the larynges harvested 2 weeks after the last injection. The remaining pigs were killed 4 months after the last injection on the remaining pigs. The vocal folds were fixed and stained with hematoxylin-eosin and trichrome and reviewed for histologic changes by 3 blinded pathologists.

Main Outcomes and Measures  Histologic changes to the vocal folds.

Results  Minimal inflammation, edema, and atypia were found in all treatment groups. No appreciable histologic differences were found among the 3 treatment groups and their controls. No difference was seen in the vocal folds that were harvested late (4 months) vs early (2 weeks) after last injection. No fibrosis was found in any of the specimens.

Conclusions and Relevance  No histologic evidence suggests that intralaryngeal cidofovir or bevacizumab alone or in combination resulted in significant changes to the porcine vocal fold. Future studies may build on this model to test higher dosages and/or may combine injections with potassium titanyl phosphate laser therapy.

×